Genomic and transcriptomic profiling of pre‐ and postneoadjuvant chemotherapy triple negative breast cancer tumors
Open Access
- 7 October 2024
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 115 (12) , 3928-3942
Abstract
Our understanding of neoadjuvant treatment with microtubule inhibitors (MTIs) for triple negative breast cancer (TNBC) remains limited. To advance our understanding of the role of breast cancer driver genes' mutational status with pathological complete response (pCR; ypT0/isypN0) prediction and to identify distinct gene sets for MTIs like eribulin and paclitaxel, we carried out targeted genomic (n = 50) and whole transcriptomic profiling (n = 64) of TNBC tumor samples from the Japan Breast Cancer Research Group 22 (JBCRG‐22) clinical trial. Lower PIK3CA, PTEN, and HRAS mutations were found in homologous recombination deficiency (HRD)‐high (HRD score ≥ 42) tumors with higher pCR rates. When HRD‐high tumors were stratified by tumor BRCA mutation status, the pCR rates in BRCA2‐mutated tumors were higher (83% vs. 36%). Transcriptomic profiling of TP53‐positive tumors identified downregulation of FGFR2 (false discovery rate p value = 2.07e‐7), which was also the only common gene between HRD‐high and ‐low tumors with pCR/quasi‐pCR treated with paclitaxel and eribulin combined with carboplatin, respectively. Differential enrichment analysis of the HRD‐high group posttreatment tumors revealed significant correlation (p = 0.006) of the glycan degradation pathway. FGFR2 expression and the differentially enriched pathways play a role in the response and resistance to MTIs containing carboplatin treatment in TNBC patients.Keywords
This publication has 39 references indexed in Scilit:
- Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple‐Negative Mammary Tumorigenesis That is Sensitive to ImmunotherapyAdvanced Science, 2021
- Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trialBreast Cancer Research and Treatment, 2021
- Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer PatientsClinical Breast Cancer, 2019
- Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment StrategiesCancer Cell, 2019
- Shed proteoglycans in tumor stromaCell and tissue research, 2016
- BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy ResistanceCancer Cell, 2011
- Frequent pathway mutations of splicing machinery in myelodysplasiaNature, 2011
- 2D Difference Gel Electrophoresis Analysis of Different Time Points during the Course of Neoplastic Transformation of Human Mammary Epithelial CellsJournal of Proteome Research, 2010
- IntegrinsCell, 2002
- Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinasesNature, 1997